19.10.2012 - Spanish Genmedica Therapeutics S.L. has raised €12m in a series B financing round led by the British investor Asclepios Bioresearch.
Genmedica develops dual action, small molecules which act against both oxidative stress and inflammation (OSIF), two processes that are emerging as critical in the pathogenesis of a wide range of diseases. It’s lead compound GMC-252 has shown in multiple type 2 diabetes animal models to act as a potent anti-diabetic, lowering glucose and lipids. „The deal with Asclepios allows us to quickly advance our clinical plans with an experienced partner and start dosing patients this year. This will allow us to generate phase 1 safety data in 2013 and preliminary efficacy data in early 2014“, stated Alec Mian, CEO of Genmedica.
In 2011, the Barcelona-based start upo raised €3m in a series A round from local investors Caxia Capital, BcnEmpren, Unifondo-Uninvest and Venture Cap.
05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. A preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.
04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.
01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.
27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.
25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.
21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.